Rankings
▼
Calendar
APLS Q2 2024 Earnings — Apellis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
APLS
Apellis Pharmaceuticals, Inc.
$3B
Q2 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$200M
+110.3% YoY
Gross Profit
$176M
88.2% margin
Operating Income
-$29M
-14.7% margin
Net Income
-$38M
-18.9% margin
EPS (Diluted)
$-0.30
QoQ Revenue Growth
+15.9%
Cash Flow
Operating Cash Flow
-$8M
Free Cash Flow
-$8M
Stock-Based Comp.
$30M
Balance Sheet
Total Assets
$904M
Total Liabilities
$640M
Stockholders' Equity
$264M
Cash & Equivalents
$360M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$200M
$95M
+110.3%
Gross Profit
$176M
$87M
+103.4%
Operating Income
-$29M
-$120M
+75.6%
Net Income
-$38M
-$122M
+69.1%
Revenue Segments
Product
$179M
90%
Licensing And Other Revenue
$21M
10%
← FY 2024
All Quarters
Q3 2024 →